277 related articles for article (PubMed ID: 17925440)
1. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
[TBL] [Abstract][Full Text] [Related]
2. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
Wang N; Lu XH; Sandoval SV; Yang XW
J Huntingtons Dis; 2013; 2(4):443-51. PubMed ID: 25062731
[TBL] [Abstract][Full Text] [Related]
3. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.
Zhang X; Smith DL; Meriin AB; Engemann S; Russel DE; Roark M; Washington SL; Maxwell MM; Marsh JL; Thompson LM; Wanker EE; Young AB; Housman DE; Bates GP; Sherman MY; Kazantsev AG
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):892-7. PubMed ID: 15642944
[TBL] [Abstract][Full Text] [Related]
4. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
[TBL] [Abstract][Full Text] [Related]
5. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
Shekhar S; Vatsa N; Kumar V; Singh BK; Jamal I; Sharma A; Jana NR
Hum Mol Genet; 2017 Jan; 26(2):420-429. PubMed ID: 28007908
[TBL] [Abstract][Full Text] [Related]
7. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.
Drouin-Ouellet J; Sawiak SJ; Cisbani G; Lagacé M; Kuan WL; Saint-Pierre M; Dury RJ; Alata W; St-Amour I; Mason SL; Calon F; Lacroix S; Gowland PA; Francis ST; Barker RA; Cicchetti F
Ann Neurol; 2015 Aug; 78(2):160-77. PubMed ID: 25866151
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model.
Im W; Ban JJ; Chung JY; Lee ST; Chu K; Kim M
Sci Rep; 2015 Nov; 5():16887. PubMed ID: 26586297
[TBL] [Abstract][Full Text] [Related]
9. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease.
Tomás-Zapico C; Díez-Zaera M; Ferrer I; Gómez-Ramos P; Morán MA; Miras-Portugal MT; Díaz-Hernández M; Lucas JJ
Hum Mol Genet; 2012 Feb; 21(3):495-510. PubMed ID: 22045698
[TBL] [Abstract][Full Text] [Related]
11. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease.
Baldo B; Paganetti P; Grueninger S; Marcellin D; Kaltenbach LS; Lo DC; Semmelroth M; Zivanovic A; Abramowski D; Smith D; Lotz GP; Bates GP; Weiss A
Chem Biol; 2012 Feb; 19(2):264-75. PubMed ID: 22365609
[TBL] [Abstract][Full Text] [Related]
12. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
13. Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease.
Safren N; El Ayadi A; Chang L; Terrillion CE; Gould TD; Boehning DF; Monteiro MJ
PLoS One; 2014; 9(1):e87513. PubMed ID: 24475300
[TBL] [Abstract][Full Text] [Related]
14. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
15. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice.
Lee J; Kosaras B; Del Signore SJ; Cormier K; McKee A; Ratan RR; Kowall NW; Ryu H
Acta Neuropathol; 2011 Apr; 121(4):487-98. PubMed ID: 21161248
[TBL] [Abstract][Full Text] [Related]
16. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
17. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
[TBL] [Abstract][Full Text] [Related]
18. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.
Spires TL; Grote HE; Garry S; Cordery PM; Van Dellen A; Blakemore C; Hannan AJ
Eur J Neurosci; 2004 May; 19(10):2799-807. PubMed ID: 15147313
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
20. Ellagic acid rescues motor and cognitive deficits in the R6/2 mouse model of Huntington's disease by lowering mutant huntingtin protein.
Sun X; Zhu J; Sun XY; Ji M; Yu XL; Liu RT
Food Funct; 2020 Feb; 11(2):1334-1348. PubMed ID: 32043503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
